Format
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 5

1.

Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.

O'Reilly MC, Scott SA, Brown KA, Oguin TH 3rd, Thomas PG, Daniels JS, Morrison R, Brown HA, Lindsley CW.

J Med Chem. 2013 Mar 28;56(6):2695-9. doi: 10.1021/jm301782e. Epub 2013 Mar 13.

2.

The phospholipase D superfamily as therapeutic targets.

Frohman MA.

Trends Pharmacol Sci. 2015 Mar;36(3):137-44. doi: 10.1016/j.tips.2015.01.001. Epub 2015 Feb 3. Review.

PMID:
25661257
3.

Expression of phospholipase D isoforms in mammalian cells.

Meier KE, Gibbs TC, Knoepp SM, Ella KM.

Biochim Biophys Acta. 1999 Jul 30;1439(2):199-213. Review.

PMID:
10425396
4.

The exquisite regulation of PLD2 by a wealth of interacting proteins: S6K, Grb2, Sos, WASp and Rac2 (and a surprise discovery: PLD2 is a GEF).

Gomez-Cambronero J.

Cell Signal. 2011 Dec;23(12):1885-95. doi: 10.1016/j.cellsig.2011.06.017. Epub 2011 Jun 29. Review.

5.

New concepts in phospholipase D signaling in inflammation and cancer.

Gomez-Cambronero J.

ScientificWorldJournal. 2010 Jul 7;10:1356-69. doi: 10.1100/tsw.2010.116. Review.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk